BRAF and malignant colon neoplasm: Significant heterogeneity in survival outcome characterizes colonic cancer patients with dysregulated BRAF expression due to the complex, and still not entirely fully elucidated, interactions between the clinical, genetic, and epigenetic landscape of BRAF expression [44].